Regeneron Pharmaceuticals Inc. depicted great volatility in its stock performance, outperforming competitors despite certain intra-day losses. Investigations into alleged drug price manipulation and fraudulent price reporting have been launched against the biotech firm. The DOJ complaint and Q1 2024 earnings that failed to meet expectations, caused the stock to dip. Despite an earnings miss and FDA's concerns over its blood cancer therapy trials, investors seem to retain interest in the firm, with the National Pension Service and Los Angeles Capital Management LLC increasing their stakes. J.P. Morgan maintains an overweight stance on the firm, backed by impressive returns.
Regeneron Pharmaceuticals REGN News Analytics from Wed, 01 Nov 2023 07:00:00 GMT to Thu, 09 May 2024 07:36:37 GMT -
Rating 0
- Innovation 3
- Information 8
- Rumor -5
